Lodestar

GRAL

GRAIL, Inc.
NasdaqServices-Medical LaboratoriesLatest fiscal year ended Dec 31, 2025

GRAIL, Inc. reported revenue of $147.17M in its most recent fiscal year, up 17.2% on the year before. It kept -277.5% of that as net income, and generated -$299.92M of free cash flow. Figures below are compared against other companies classified under Services-Medical Laboratories.

Grades vs. industry

No grades available. Grades compare a company against others sharing its industry classification, and this one does not have enough classified peers with reported figures to support a meaningful comparison.

Growth

MetricCompanyIndustry medianRank
Revenue growth (YoY)
Latest fiscal year revenue vs. the year before.
17.2%13.8%—
Revenue growth (3y)
Annualized revenue growth over three fiscal years.
38.4%12.5%—
Revenue growth (5y)
Annualized revenue growth over five fiscal years.
Not reported11.7%—
EPS growth (YoY)
Diluted EPS vs. the prior fiscal year.
Not reported-143.0%—
EPS growth (3y)
Annualized diluted EPS growth over three fiscal years.
Not reported——
EPS growth (5y)
Annualized diluted EPS growth over five fiscal years.
Not reported——
Free cash flow growth (YoY)
Operating cash flow less capital expenditure, vs. prior year.
Not reported29.8%—
Free cash flow growth (3y)
Annualized free cash flow growth over three fiscal years.
Not reported——

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Profitability

MetricCompanyIndustry medianRank
Gross margin
Gross profit as a share of revenue. Often unreported.
Not reported58.3%—
Operating margin
Operating income as a share of revenue.
-382.0%-12.8%—
Net margin
Net income as a share of revenue.
-277.5%-9.0%—
Free cash flow margin
Free cash flow as a share of revenue.
-203.8%-3.1%—
Return on equity
Net income divided by shareholder equity.
-15.8%-6.8%—
Return on assets
Net income divided by total assets.
-14.0%-6.0%—
Return on invested capital
After-tax operating profit over debt plus equity less cash.
-19.1%-10.2%—

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Financial health

MetricCompanyIndustry medianRank
Debt to equity
Total debt divided by shareholder equity.
Not reported0.66x—
Current ratio
Current assets over current liabilities.
11.97x3.39x—
Quick ratio
Current assets excluding inventory, over current liabilities.
11.97x3.24x—
Interest coverage
Operating income divided by interest expense.
Not reported-3.44x—
Net debt to EBITDA
Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed.
Not reported1.51x—

top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.

“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.

Insider activity

Trades reported by officers, directors and 10% shareholders on SEC Form 4. None of the last 26 reported transactions were open-market purchases — grants, option exercises and sales make up the majority of insider filings at most companies.

DateInsiderTransactionSharesPriceValue
Oct 15, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale7,052$136.83$964.9K
Oct 15, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale6,034$137.63$830.5K
Oct 15, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale3,400$135.44$460.5K
Oct 15, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale2,114$138.79$293.4K
Oct 15, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale1,000$134.38$134.4K
Oct 15, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale400$133.12$53.2K
Oct 15, 2026
SUMME GREGORY L
Director
Grant or award237$135.46$32.1K
Oct 15, 2026
CHASE WILLIAM J
Director
Grant or award153$135.46$20.7K
Oct 15, 2026
MIZELL STEVEN
Director
Grant or award148$135.46$20.0K
Oct 5, 2026
Freidin Aaron
Chief Financial Officer
Open-market sale23,619$146.39$3.46M
Oct 5, 2026
Partridge Andrew John
Chief Growth Officer
Open-market sale7,873$146.39$1.15M
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale37,752$94.98$3.59M
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale10,000$110.00$1.10M
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale6,200$96.43$597.9K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Option exercise26,452$14.00$370.3K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale2,100$100.68$211.4K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale2,125$92.32$196.2K
Sep 21, 2026
Freidin Aaron
Chief Financial Officer
Open-market sale1,800$93.92$169.0K
Sep 21, 2026
Freidin Aaron
Chief Financial Officer
Open-market sale1,779$92.26$164.1K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale1,400$97.84$137.0K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale1,454$93.61$136.1K
Sep 21, 2026
Freidin Aaron
Chief Financial Officer
Open-market sale521$95.00$49.5K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Open-market sale421$99.85$42.0K
Sep 21, 2026
Ofman Joshua J.
Chief Executive Officer
Option exercise(derivative)26,452$0.00$0.00
Aug 27, 2026
Freidin Aaron
Chief Financial Officer
Open-market sale7,900$85.01$671.6K

A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.

Annual financials

Fiscal year202520242023 Dec2023 Jan
Revenue$147.17M$125.59M$93.11M$55.55M
Operating income-$562.16M-$2.19B-$1.52B-$5.44B
Net income-$408.35M-$2.03B-$1.47B-$5.40B
EPS (diluted)-$11.11-$63.54-$47.21-$173.89
Operating cash flow-$299.01M-$577.16M-$595.80M-$561.31M
Capital expenditure$909.0K$5.21M$12.89M$22.86M
Free cash flow-$299.92M-$582.36M-$608.69M-$584.17M
Total assets$2.92B$2.98B$3.91B—
Shareholder equity$2.58B$2.50B——
Cash$249.73M$214.23M$97.29M$241.60M

A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.

Source

Figures come from GRAIL, Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 12, 2026. View filings on EDGAR.

Not financial advice. This page presents figures reported to the SEC and compares them with other companies sharing an industry classification. It is not a recommendation to buy or sell anything, and the grades cannot capture everything that matters about a business. Industry classifications are coarse, filings are self-reported, and some figures are missing or understated where companies tag them in ways this site does not match. Do your own research.